NEW ORLEANS, LA—A novel transcatheter intracardiac shunt device appears to provide sustained clinical benefit at 1 year in heart failure patients with preserved or only mildly reduced ejection ...

An FDA advisory panel unanimously agreed that Johnson & Johnson MedTech's V-Wave Ventura interatrial shunt's risks outweigh ...

Brian Fahey explains how Adona Medical uses heat to adjust its novel shape memory nitinol implant without harming heart ...

Sponsor seeks approval based on sliced and diced data ...

J&J is pursuing premarket approval for the heart shunt. Although advisory committees provide recommendations to the FDA, the ...

An FDA panel unanimously rejected J&J's V-Wave Ventura heart shunt, citing risks outweighing benefits despite safety data.

ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

The first implantation of a new device called interatrial shunt device (IASD) is a success. This device is developed by Corvia Medical. The device is a non-surgical device that provides continuous ...

Please provide your email address to receive an email when new articles are posted on . Physiologic aqueous outflow pathways include the conventional outflow pathway and the uveoscleral outflow.

The US Food and Drug Administration (FDA) is warning healthcare providers about potential hazards from interactions between implanted programmable cerebrospinal fluid (CSF) shunts and hearing implants ...